China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more crowded with the looming entry of generics.

(Bloomberg) -- Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the fast-growing weight loss market. The American drugmaker struck a ...

A UK regulator reprimanded Sanofi for making misleading claims about its RSV shot and disparaging rival Pfizer Inc.’s vaccine. The French drugmaker breached the industry’s own code of practice by ...

(Bloomberg) -- Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile ...

Pfizer has reached a turning point.

Pfizer Inc. said that a monthly regimen of an obesity drug obtained in its deal for Metsera Inc. produced up to 12.3% weight loss after 28 weeks compared to a placebo. from the mid-stage study shows ...